| RET, ROS1 and ALK fusions in lung cancer. | |
| | |
MedLine Citation:
|
PMID: 22327623 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for ROS1. In addition, we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas. A multivariate analysis of 1,116 adenocarcinomas containing these 71 kinase-fusion-positive adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase-fusion status. |
| | |
Authors:
|
Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa |
Related Documents
:
|
20495373 - Map kinase phosphorylation is dispensable for cell division, but required for cell grow... 23142633 - Ror2-src signaling in metastasis of mouse melanoma cells is inhibited by nrage. 22836613 - Tiotropium increases pparγ and decreases creb in cells isolated from induced sputum of... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-2-12 |
Journal Detail:
|
Title: Nature medicine Volume: - ISSN: 1546-170X ISO Abbreviation: - Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-2-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502015 Medline TA: Nat Med Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1] Pathology Project for Molecular Targets, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. [2] Division of Pathology, the Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Next Document: KIF5B-RET fusions in lung adenocarcinoma.